Market research
SRDX SurModics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 615M
- P/E ratio
- Not available
- Analyst target
- 43
- Dividend yield
- Not available
- Beta
- 1.39
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US8688731004
- Market cap
- 615M
- P/E ratio
- Not available
- Analyst target
- 43
- Dividend yield
- Not available
- Beta
- 1.39
About
About SurModics Inc
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SRDX discussion.
5 years, 4 months ago
Surmodics, Inc is currently in a long term uptrend where the price is trading 11.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.5.
Surmodics, Inc's total revenue sank by 1.4% to $22M since the same quarter in the previous year.
Its net income has dropped by 100.0% to $62 since the same quarter in the previous year.
Finally, its free cash flow fell by 116.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Surmodics, Inc gets an overall score of 2/5.